Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Blood Cancer Journal|October 7, 2020
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use programFabio Guolo, Luana Fianchi, Paola Minetto, et al.
Cancer|March 22, 2025
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemiaCristina Papayannidis, Elisabetta Petracci, Patrizia Zappasodi, et al.
British Journal of Haematology|November 6, 2022
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL studyMichelina Dargenio, Massimiliano Bonifacio, Sabina Chiaretti, et al.
Cancers|March 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE StudyStefano Molica, Potito Rosario Scalzulli, Lydia Scarfò, et al.
Annals of Hematology|August 26, 2025
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL groupDavide Lazzarotto, Anna Maria Testi, Matteo Fanin, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2016
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trialsMassimo Gentile, Katja Zirlik, Stefania Ciolli, et al.
Haematologica|October 10, 2024
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapyFederico Mosna, Erika Borlenghi, Mark Litzow, et al.
Cancers|March 28, 2024
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE StudyFrancesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò, et al.
American Journal of Hematology|January 14, 2014
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patientsRobin Foà, Ilaria Del Giudice, Antonio Cuneo, et al.
Hematological Oncology|May 9, 2025
Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient PopulationMassimo Breccia, Antonella Russo Rossi, Valentina Giai, et al.
Pageof 15